Abstract
Switching from the concept of substance or alcohol dependence to that of addiction has profoundly modified our ways of approaching, treating and organizing the care of this disease. This more complex and subtle approach gives less importance to the substance and its effects and focuses more on the initiation of pathological behavior. It is important to keep in mind that the addictive process associates a substance (more or less addictive), an individual (more or less vulnerable) and an environment (more or less condoning). Today, it is no longer possible to consider that a drug acts on only one receptor or one system. Current understanding of inner regulation mechanisms integrates the interactions between the various stimulated brain pathways. Addiction treatments which should benefit from advances in genetics, neuropsychology and neuroimaging could be increasingly individualized in the years to come. The “addictology” approach has triggered thinking about other therapeutic approaches such as modification of therapeutic objectives toward “risk reductions” or applying this model to behavioral addictions (food, sex, sport, gaming…)
Keywords: Addiction, individual vulnerability, behavioural, environment, DSM-V, neuropsychology, neuroimaging, addictology, vulnerable, polysubstance, epigenetic, psychology, acetylcholine, neurokinine, glutamate, medications, diagnostic, pertinent, polymorphisms
Current Pharmaceutical Design
Title: From Substance Dependence to Addiction: Impact of a Conceptual Shift on Therapeutic Approaches?
Volume: 17 Issue: 14
Author(s): Michel Reynaud and Laurent Karila
Affiliation:
Keywords: Addiction, individual vulnerability, behavioural, environment, DSM-V, neuropsychology, neuroimaging, addictology, vulnerable, polysubstance, epigenetic, psychology, acetylcholine, neurokinine, glutamate, medications, diagnostic, pertinent, polymorphisms
Abstract: Switching from the concept of substance or alcohol dependence to that of addiction has profoundly modified our ways of approaching, treating and organizing the care of this disease. This more complex and subtle approach gives less importance to the substance and its effects and focuses more on the initiation of pathological behavior. It is important to keep in mind that the addictive process associates a substance (more or less addictive), an individual (more or less vulnerable) and an environment (more or less condoning). Today, it is no longer possible to consider that a drug acts on only one receptor or one system. Current understanding of inner regulation mechanisms integrates the interactions between the various stimulated brain pathways. Addiction treatments which should benefit from advances in genetics, neuropsychology and neuroimaging could be increasingly individualized in the years to come. The “addictology” approach has triggered thinking about other therapeutic approaches such as modification of therapeutic objectives toward “risk reductions” or applying this model to behavioral addictions (food, sex, sport, gaming…)
Export Options
About this article
Cite this article as:
Reynaud Michel and Karila Laurent, From Substance Dependence to Addiction: Impact of a Conceptual Shift on Therapeutic Approaches?, Current Pharmaceutical Design 2011; 17 (14) . https://dx.doi.org/10.2174/138161211796150800
DOI https://dx.doi.org/10.2174/138161211796150800 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Assessment and Relevance of Carotid Intima-Media Thickness (C-IMT) in Primary and Secondary Cardiovascular Prevention
Current Pharmaceutical Design Study of the Effects of L-tryptophane Nanoparticles on Motor Behavior in Alzheimer's Experimental Models
CNS & Neurological Disorders - Drug Targets Preface
Current Molecular Medicine Dissecting Cause and Effect in the Pathogenesis of Psychiatric Disorders: Genes, Environment and Behaviour
Current Molecular Medicine Transient Disruption of Fear-Related Memory by Post-Retrieval Inactivation of Gastrin-Releasing Peptide or N-Methyl-D-Aspartate Receptors in the Hippocampus
Current Neurovascular Research Adeno-Associated Viral Vectors for Retinal Gene Transfer and Treatment of Retinal Diseases
Current Gene Therapy Combination Treatment in Alzheimers Disease: Results of a Randomized, Controlled Trial with Cerebrolysin and Donepezil
Current Alzheimer Research Prognostic Significance of Asymptomatic Myocardial Ischemia in Women vs. Men
Current Pharmaceutical Design A Computational Molecular Docking Studies on the Tryparedoxin Peroxidase of <i>Leishmania donovani</i> Responsible for Visceral Leishmaniasis in Human
Letters in Drug Design & Discovery Pediatric Immune Dysfunction and Health Risks Following Early-Life Immune Insult
Current Pediatric Reviews Pertussis Toxin (PTX) and its Non-Toxic Derivatives as Vaccine Adjuvant and Microbicide
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Remembrance and Historicization: The Transformation of Individual and Collective Trauma and its Transgenerational Consequences
Adolescent Psychiatry Would Some Herbal Teas Play a Medicating Role for Certain Diseases?
Current Nutrition & Food Science Personalized Medicine: Pharmacogenetics in Psychiatry
Current Pharmacogenomics and Personalized Medicine Meet Our Editorial Board Members:
Central Nervous System Agents in Medicinal Chemistry High Contrast and Resolution Labeling of Amyloid Plaques in Tissue Sections from APP-PS1 Mice and Humans with Alzheimer’s Disease with the Zinc Chelator HQ-O: Practical and Theoretical Considerations
Current Alzheimer Research Biological Basis of Ageing, Age-related Diseases and Interventions
Current Pharmacogenomics and Personalized Medicine The Risk That DSM-5 Will Affect the Way We See Ourselves
Current Psychiatry Reviews Glioma: Tryptophan Catabolite and Melatoninergic Pathways Link microRNA, 14-3- 3, Chromosome 4q35, Epigenetic Processes and other Glioma Biochemical Changes
Current Pharmaceutical Design PET Tracers for Serotonin Receptors and Their Applications
Central Nervous System Agents in Medicinal Chemistry